Company intelligence / Profile preview

Exsurgo

Ownership: Private
Development stage: Other

Overview

The Axon device has demonstrated efficacy in reducing chronic pain intensity and improving quality of life metrics such as mood and sleep. Clinical trials have shown reduced dependency on medications among users. Registered with FDA for chronic pain treatment; CE marked in EU.

Therapeutic areas: PsychiatryNeurologyOther
Modalities: DeviceNon-pharmacological therapy (Neurofeedback device)
Industry: Therapeutic Medical Devices

Partnerships

Collaborations implied with clinical sites in UK/NZ/UAE

Beyond the preview

Go deeper on Exsurgo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exsurgo.

Explore the full profile